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John K. Finkb and Rudy J. Richardsonb,c*ABSTRACT: Inhibition and aging of neuropathy target esterase (NTE) by neuropathic organophosphorus (OP) compounds
triggers OP compound-induced delayed neuropathy (OPIDN), whereas inhibition of acetylcholinesterase (AChE) produces cholin-
ergic toxicity. The neuropathic potential of an OP compound is deﬁned by its relative inhibitory potency toward NTE vs. AChE
assessed by enzyme assays following dosing in vivo or after incubations of direct-acting compounds or active metabolites with
enzymes in vitro. The standard animal model of OPIDN is the adult hen, but its large size and high husbandry costs make this
species a burdensome model for assessing neuropathic potential. Although the mouse does not readily exhibit clinical signs of
OPIDN, it displays axonal lesions and expresses brain AChE and NTE. Therefore, the present research was performed as a further
test of the hypothesis that inhibition of mouse brain AChE and NTE could be used to assess neuropathic potential using mouse
brain preparations in vitro or employing mouse brain assays following dosing of OP compounds in vivo. Excellent correlations
were obtained for inhibition kinetics in vitro of mouse brain enzymes vs. hen brain and human recombinant enzymes. Further-
more, inhibition of mouse brain AChE and NTE after dosing with OP compounds afforded ED50 ratios that agreed with relative
inhibitory potencies assessed in vitro. Taken together, results with mouse brain enzymes demonstrated consistent correspon-
dence between in vitro and in vivo predictors of neuropathic potential, thus adding to previous studies supporting the validity
of a mouse model for biochemical assessment of the ability of OP compounds to produce OPIDN. Copyright © 2014 John Wiley
& Sons, Ltd.
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Organophosphorus (OP) compounds inhibit serine esterases by
organophosphylation of the active site serine (Aldridge and
Davison, 1953; Richardson, 2010). The inhibited enzyme can
undergo aging, which involves net loss of a side chain from
the OP moiety to yield a stable negatively charged species still
attached to the active site serine.
Inhibition of acetylcholinesterase (AChE) produces cholinergic
toxicity regardless of whether or not aging has occurred. In
contrast, both inhibition and aging of neuropathy target ester-
ase (NTE) are required to cause OP compound-induced delayed
neurotoxicity (OPIDN), a distal degeneration of long, large diam-
eter sensorimotor axons in spinal cord and peripheral nerves
resulting in sensory loss and paralysis (Richardson et al., 2013).
Although there are many causes of peripheral neuropathy
(Hughes, 2002), including chronological aging and diabetes
(Callaghan et al., 2012; Singer et al., 2012), OPIDN is a speciﬁc
chemically induced disorder that involves a combination of
peripheral neuropathy and axonopathy in spinal cord tracts
(Richardson, 2005). Moreover, whereas AChE inhibition, acute
stress and inﬂammatory stimuli can induce changes in AChE
gene expression and microRNAs targeting AChE (Evron et al.,
2007; Kaufer et al., 1998; Shaked et al., 2009), AChE inhibition is
not involved in the etiology of OPIDN (Lotti, 1992).J. Appl. Toxicol. 2014; 34: 1426–1435 Copyright © 2014 JohnWhen an OP compound is substantially more potent as an
inhibitor of AChE than of NTE, cholinergic toxicity could result
in lethality, thus obviating the development of OPIDN. However,
when an OP compound is neuropathic, cholinergic toxicity will
be mild, and sufﬁcient NTE can be inhibited and aged to initiate
OPIDN. Accordingly, earlier studies with enzymes from hen and
human brain have shown that the neuropathic potential of an
OP compound can be assessed by its relative inhibitory potency
(RIP) against NTE vs. AChE (Kropp and Richardson, 2003; Lotti
and Johnson, 1978).
Apart from inhibition and aging of NTE, the pathogenic
mechanisms that transpire between exposure to a neuropathic
OP compound and the emergence of OPIDN 1–4 weeks laterWiley & Sons, Ltd.
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Figure 1. Structures of test compounds.
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142are poorly understood. Elucidation of the pathogenesis and
mechanism of OPIDN, as well as the assessment of OP compounds
for their neuropathic potential, have been hampered by gaps in
knowledge concerning the physiological function of NTE and
deﬁciencies in available models, either in vivo or in vitro
(Pomeroy-Black et al., 2007). Thus, it has been difﬁcult to develop
models that accommodate such features as the apparent need
for axons of sufﬁcient length and caliber, higher susceptibility of
adult vs. young animals, and species differences in the biotrans-
formation of OP compounds and turnover rates of NTE and other
nervous system proteins (Moretto and Lotti, 2002).
Currently, the most widely accepted animal model for the
study of OPIDN or assessment of the neuropathic potential of
OP compounds is the adult hen (Doherty, 2006; Emerick et al.,
2012). However, compared to the usual laboratory rodents
(e.g. rats or mice), hens are difﬁcult to acquire and maintain for
laboratory studies, and their substantially larger size requires
considerably greater amounts of test materials for dosing.
Consequently, it would be of interest to develop a rodent model
for studying at least some aspects of OPIDN and/or for assessing
the neuropathic potential of OP compounds.
Among rodents, rats have been thought to be resistant to
OPIDN, because they do not readily display clinical signs of
hindlimb paralysis, despite exposure to high levels of neuro-
pathic compounds (Abou-Donia, 1981). Mice have been consid-
ered even less suitable than rats as models for OPIDN, because
of the difﬁculty in producing clinical signs and achieving
suprathreshold (> 70%) inhibition of neural NTE in vivo following
dosing with neuropathic OP compounds (Veronesi et al., 1991).
Nevertheless, mice develop axonal lesions and express brain
AChE and NTE activities that are inhibited in a dose-related man-
ner by OP compounds (Lapadula et al., 1985; Read et al., 2010).
Moreover, owing to the rapid turnover of mouse brain NTE
(Meredith and Johnson, 1988), higher levels of inhibition can be
seen by assaying the enzyme at shorter intervals than 24–72 h
after dosing (Read et al., 2010), as was the practice in earlier studies
using mice or hens (Malygin et al., 2003; Veronesi et al., 1991).
The present work was carried out as a further test of the
hypothesis that inhibition of mouse brain AChE and NTE
in vitro and in vivo could be used to assess the neuropathic
potential of OP compounds. Using OP compounds spanning
several orders of magnitude in inhibitory potency toward each
enzyme, we determined bimolecular rate constants of inhibition
(ki) for mouse brain AChE and NTE, calculated RIPs, and
examined the correlations of these values with those obtained
for hen brain AChE and NTE as well as human recombinant AChE
and NTE esterase domain (NEST). In addition, to evaluate the
capability of the mouse model for assessing neuropathic potential
in vivo, we determined 24 h LD50 values as well as ED50 values from
dose–response curves for mouse brain AChE and NTE inhibition
soon (1 h) after dosing by three OP compounds that differed in
neuropathic potential as assessed in vitro. The structures of the
OP compounds used in the present study are shown in Fig. 1.
Materials and Methods
Chemicals
Phenyl valerate (PV), N,N′-di-2-propylphosphorodiamidoﬂuoridate
(mipafox, MIP), O,O-di-1-propyl-O-2,2-dichlorovinyl phosphate
(PrDChVP), O,O-diethyl-O-(1-triﬂuoromethyl-2,2,2-triﬂuoroethyl)
phosphate (diEt-PFP) and O,O-dibutyl-O-(1-triﬂuoromethyl-2,2,J. Appl. Toxicol. 2014; 34: 1426–1435 Copyright © 2014 John2-triﬂuoroethyl) phosphate (diBu-PFP) were synthesized and
characterized in the Institute of Physiologically Active Compounds,
Russian Academy of Sciences (IPAC, RAS, Chernogolovka, Russia)
and kindly furnished by Dr. Alexey Aksinenko. Syntheses have also
been previously described for PV and MIP (Johnson, 1977),
PrDChVP (Allen and Johnson, 1955), and diEt-PFP and diBu-PFP
(Makhaeva et al., 2008, 2009a). The purity of all substances
produced by IPAC, RAS was > 99% (by spectral and chrom-
atographic analysis). O,O-diisopropylphosphoroﬂuoridate (DFP; >
90%, gas chromatography–mass spectrometry, GC/MS) and O,
O-diethyl-4-nitrophenyl phosphate (paraoxon, PO; > 90%,
GC/MS) were purchased from Sigma-Aldrich (St. Louis, MO, USA);
O,O-diethyl-O-(3,4,5-trichloro-2-pyridyl) phosphate (chlorpyrifos
oxon, CPO;> 96%, GC), was kindly furnished by DowAgroSciences
(Indianapolis, IN, USA); O,O-diethyl-O-(3,4,5-trichloro-2-pyridyl)
phosphorothioate (chlorpyrifos, CPS; > 99%, GC), was provided
by Dow Chemical (Midland, MI, USA). All other chemicals were
analytical grade or the highest grade commercially available and
used without further puriﬁcation. Aqueous solutions were
prepared using deionized water.Animals
All experiments with animal subjects were carried out according
to protocols for the use and care of laboratory animals approved
by the Institute of Physiologically Active Compounds, RAS
(Chernogolovka, Russia) or the University Committee on Use
and Care of Animals (Ann Arbor, MI, USA). Adult white Leghorn
hens were from the Department of Animal Science, Michigan
State University (East Lansing, MI, USA) or Noginsk poultry farm
(Noginsk, Russia). Adult male and/or female C57BL mice (18–28
g, 3 mo of age) from the University of Michigan Department of
Neurology colony (Ann Arbor, MI, USA) or outbred male CD-1
albino mice (20–24 g, 2 months of age) (Pushchino, Russia) were
used. Hens were housed three per stainless steel cage at 20–23 °
C and fed laying mash (Purina, St. Louis, MO, USA; or Assortment-
Agro, Sergiev Posad, Russia) and tap water ad libitum. Mice wereWiley & Sons, Ltd. wileyonlinelibrary.com/journal/jat
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1428housed six to eight per plastic shoebox cage at 22–24 °C and fed
mouse chow (Purina; or Assortment-Agro) and tap water ad libitum.Hen brain and mouse brain acetylcholinesterase and
neuropathy target esterase preparations
Animals were killed via CO2 asphyxiation. Brains were immedi-
ately removed, weighed, frozen in dry ice or liquid nitrogen,
and stored at 80 °C until use. Frozen brains were thawed and
homogenized in 0.32 M sucrose at 4 °C. Homogenates were
centrifuged 9000 g for 20 min at 4 °C. Aliquots of the superna-
tants (brain 9S fraction) were stored at80 °C until use. For some
experiments with hen brain NTE, a lyophilized membrane frac-
tion consisting of combined mitochondrial/synaptosomal and
microsomal pellets (P2 + P3) (Richardson et al., 1979)
preinhibited with PO (40 μM at 25°C for 45 min) was used
(Makhaeva and Malygin, 1999; Makhaeva et al., 1998). For a
given enzyme and species, no signiﬁcant differences in ki values
for a speciﬁc inhibitor were found between enzyme sources
(data not shown).Human recombinant acetylcholinesterase and neuropathy
target esterase domain
To avert the logistical and biohazard issues accompanying the
use of human tissues and to take advantage of the availability
of pure human enzymes, human recombinant enzymes were
used. Human recombinant AChE was obtained from Sigma-
Aldrich. Because full-length NTE is difﬁcult to isolate or produce,
NEST was used as a surrogate. NEST was prepared and puriﬁed
as previously described (Atkins and Glynn, 2000; Atkins et al.,
2002) using a human brain plasmid kindly supplied by Dr. Paul
Glynn of the MRC Toxicology Unit (Leicester, UK). Comprising
the active site serine, NEST is the shortest segment of NTE that
retains esterase activity; moreover, the catalytic properties of
NEST, including its response to OP inhibitors, closely resemble
those of full-length NTE (Kropp et al., 2004; Makhaeva et al.,
2010; Van Tienhoven et al., 2002).Protein assay
Protein was assayed by the Coomassie blue dye-binding method,
with bovine serum albumin as a standard (Bradford, 1976).Acetylcholinesterase activity and inhibition
AChE was inhibited by preincubation with OP compounds
(Makhaeva et al., 2010) and its residual activity determined by
a modiﬁcation of a colorimetric assay (Ellman et al., 1961). Brieﬂy,
stock solutions of inhibitors in water-miscible organic solvents
(acetone or dimethyl sulfoxide, DMSO) were serially diluted to
appropriate working concentrations in 50 mM Tris-citrate buffer
(pH 6.0 at 25 °C), so that the ﬁnal organic solvent concentration
in the preincubation mixture was ≤ 1% (v/v), a concentration
range previously shown to have no signiﬁcant effect on enzyme
activity. Enzyme preparations in 100mM sodium phosphate buffer
pH 8.0 (250 μl) were preincubated with inhibitor working solutions
(50 μl) at 37 °C for measured times, e.g. 0, 3, 6, 9 and 12 min. At the
end of each preincubation interval, 50 μl of the preincubated
enzyme mixture was added to 200 μl prewarmed substrate
solution containing 1.25 mM acetylthiocholine and 0.4 mM 5,5′-
dithio-bis(2-nitrobenzoic acid) in 96-well plates, and the activityCopyright © 2014 Johnwileyonlinelibrary.com/journal/jatof AChE at 37 °C wasmeasured by the rate of change in absorbance
at 412 nm using a SpectraMax 340 (Sunnyvale, CA, USA) or Bio-Rad
Benchmark Plus (St. Grégoire cédex, France) microplate reader.Neuropathy target esterase or neuropathy target esterase
domain activity and inhibition
NTE or NEST was inhibited by preincubation with OP compounds
(Makhaeva et al., 2010) as described above for AChE inhibition,
and its residual activity determined by a modiﬁcation of a
colorimetric assay (Kayyali et al., 1991). All reactions were carried
out at 37 °C for the entire assay. Homogenates were diluted in
50 mM Tris–HCl, 0.1 mM EDTA, pH 8.0 at 37 °C. NTE activity was
deﬁned as the PV hydrolase activity inhibited by preincubation
for 20 min with 40 μM PO but not abolished by preincubation
for 20 min with 40 μM PO plus 250 μM MIP. When the lyophilized
hen brain NTE preparation was used, PO was omitted from the
preincubation step, because this preparation was previously
preincubated with PO. For NEST activity, no preincubation with
PO or MIP was required, because no other esterases are present
(Kropp et al., 2004). Test inhibitors were prepared and diluted as
described in the section above on measurement of AChE activity
and inhibition. For NTE, test inhibitors were added at the end of
the ﬁrst preincubation interval and inhibition was continued for
various measured times, usually between 0 and 20 min, before
addition of substrate (Kropp and Richardson, 2003). For NEST, no
preincubation with PO or PO plus MIP was required; therefore, test
inhibitors were added to NEST preparations and inhibition allowed
to progress for various measured times. At the end of the ﬁnal
preincubation interval, substrate solution (100 μl) consisting of
5.3 mM PV/N,N’-dimethylformamide diluted in 0.03% (w/v) Triton
X-100 was added, and the reaction was allowed to proceed for
20 min, during which PV was hydrolyzed by active NTE or NEST
to produce phenol. Stop solution (100 μl) of 5.0 mg ml–1 sodium
dodecyl sulfate/1.23 mM 4-aminoantipurine was added, and the
reaction of 4-aminoantipurine with the phenol product was
allowed to proceed for 3 min. The chromophore was produced
by adding 50 μl of 12.1 mM K3Fe(CN)6, and color was allowed to
develop and stabilize for 10 min. The endpoint absorbance was
measured at 486 nm using a SpectraMax 340 or Bio-Rad Bench-
mark plus microplate reader.Calculation of bimolecular rate constants of inhibition, ki
The apparent ki, values of OP inhibitors against esterases were
determined as described previously (Doorn et al., 2003; Kropp
and Richardson, 2003; Richardson, 1992). Brieﬂy, slopes of primary
linear kinetic plots of ln (% activity) vs. time gave the apparent
ﬁrst-order rate constants of inhibition (k′) for each [I], and the
slope of the secondary linear kinetic plot of –k′ vs. [I] gave the
ki for each inhibitor.In vivo inhibition of acetylcholinesterase and neuropathy
target esterase in mouse brain
In vivo experiments were carried out on outbred male white
mice (18–25 g). PrDChVP, diEt-PFP and diBu-PFP were dissolved
in DMSO and injected i.p. in a volume of approximately 0.1 ml in
ﬁve to 12 increasing doses of each tested compound. For each
dose, at least six animals were used. Control animals for diEt-PFP
and diBu-PFPwere injected only with DMSO. Because of the higher
cholinergic toxicity of PrDChVP, mice in this group were givenJ. Appl. Toxicol. 2014; 34: 1426–1435Wiley & Sons, Ltd.
Mouse model for biochemical OPIDN assessmentatropine sulfate, 20 mg kg–1 i.p. in water 20 min before injection
with the OP compound; in this case, control animals received atro-
pine sulfate and DMSO. After 1 h, mice were decapitated under CO2
anesthesia and brains removed for the determination of NTE and
AChE activities. Brains were weighed, frozen in liquid nitrogen
and stored at 80 °C until use. For assay, brains were thawed and
each brain was homogenized at 4 °C in ﬁve volumes of buffer
(50 mM Tris–HCl, 0.2 mM EDTA, pH 8.0) with a Potter homogenizer.
The homogenates were centrifuged (15 min at 9000 × g at 4°C) to
prepare the 9S supernatant used for enzyme assay (Padilla and
Veronesi, 1985). Aliquots of the supernatants (brain 9S fraction)
were stored at 80 °C until use. Esterase activity in brain frommice
treated with the OP compounds (OP compound plus atropine for
PrDChVP) was determined and compared to activity in tissue sam-
ples from animals treated with DMSO or DMSO plus atropine.Acute toxicity assessment
The 24 h acute i.p. toxicity of PrDChVP, diEt-PFP and diBu-PFP was
determined in outbred male white mice weighing 18–25 g, using
ﬁve to seven dose levels per compound and six to eight animals
per dose level.Statistical analysis
Data are expressed as means ± SEM or mean and 95% CI. Plots,
regressions and correlations were carried out using Origin 6.1
software, OriginLab Corp. (Northampton, MA, USA), Prism 6.0 for
Windows, or Prism 6d for Mac OS X, GraphPad Software, Inc.
(San Diego, CA, USA). LD50 values were calculated by probit anal-
ysis using BioStat 2006 (AnalystSoft, Alexandria, VA, USA).Results
Inhibition of acetylcholinesterase and neuropathy target
esterase/neuropathy target esterase domain in vitro
Tables 1 and 2 list the experimental ki and corresponding
calculated IC50 values obtained in the present study for CPS,Table 1. Experimental ki and calculated 20 min IC50 values f
acetylcholinesterasea
Inhibitor S
Hen M
ki IC50 ki
CPS NI ND NI
CPO 1.06 ± 0.07 × 107 3.27 ± 0.22 × 10–9 1.13 ± 0.03 × 1
DFP 1.43 ± 0.05 × 105 2.42 ± 0.08 × 10–7 9.89 ± 0.61 × 1
MIP 1.14 ± 0.07 × 103 3.03 ± 0.19 × 10–5 4.64 ± 0.60 × 1
PrDChVP 3.60 ± 0.12 × 105 9.62 ± 0.32 × 10–8 3.70 ± 0.22 × 1
diEt-PFP 1.11 ± 0.06 × 103 3.12 ± 0.17 × 10–5 7.22 ± 0.36 ×10
diBu-PFP 1.80 ± 0.14 × 105 1.92 ± 0.15 × 10–7 7.12 ± 0.33 × 1
ND, Not determined; NI, no inhibition at the highest concentration
aValues are mean ± SEM (n = 3 or 4). Fixed-time (20 min) IC50 values
IC50 = inhibitor concentration to produce 50% inhibition of the enz
constant of inhibition, and t = preincubation time with inhibitor = 2
acetylcholinesterase activity was assayed in 9S fractions from bra
preparations from commercial recombinant enzyme.
J. Appl. Toxicol. 2014; 34: 1426–1435 Copyright © 2014 JohnCPO, DFP, MIP, PrDChVP, diEt-PFP and diBu-PFP against AChE
and NTE or NEST from different sources (hen brain, mouse brain
and human recombinant enzymes). There was good agreement
in inhibitory potency for a given inhibitor across species for
AChE and for NTE or NEST. Moreover, correlations of log ki values
for mouse brain with those for hen brain or human recombinant
enzymes were excellent (r > 0.99), as was the correlation be-
tween log ki values for human and hen enzymes (Figs 2 and 3).
Table 3 shows the RIP values calculated from the respective ki
data given in Tables 1 and 2. The results predict that CPO is
highly cholinergic (RIP << 1), whereas DFP and diEt-PFP are
slightly cholinergic (RIP < 1), and MIP, PrDChVP and diBu-PFP
are neuropathic (RIP > 1). In addition, there were strong correla-
tions (r > 0.97) of log RIP values for mouse brain enzymes with
those obtained from either hen brain or human recombinant
enzymes, as well as between log RIP values for human and
hen enzymes (Fig. 4).Inhibition of acetylcholinesterase and neuropathy target
esterase in mouse brain in vivo
Inhibition of AChE and NTE in mouse brain was determined 1 h
after i.p. administration of increasing doses of the known neuro-
pathic OP compound PrDChVP and two new OP compounds
possessing different neuropathic potentials according to
in vitro data: diEt-PFP (slightly cholinergic) and diBu-PFP (neuro-
pathic). The data obtained in three series of in vivo experiments
are shown in Fig. 5.
For PrDChVP (Fig. 5A), inhibition of both AChE and NTE in
mouse brain was relatively potent and dose-dependent, yielding
ED50 values of 4.34 ± 0.55 mg kg
–1 for AChE and 2.17 ± 0.37 mg
kg–1 for NTE. In contrast, diEt-PFP produced relatively low
inhibition of AChE and especially NTE at 1 h after dosing, and
unambiguous ED50 values could not be calculated. However, at
the maximum dose of 200 mg kg–1 diEt-PFP, AChE activity was
reduced to 26% and NTE to 14% of control (Fig. 5B). For diBu-
PFP, both enzymes were inhibited in a dose-dependent manner
(Fig. 5C), yielding ED50 values of 516 ± 83.9 mg kg
–1 for AChE
and 127 ± 7.5 mg kg–1 for NTE.or organophosphorus inhibitors against different species of
pecies
ouse Human
IC50 ki IC50
ND NI ND
07 3.07 ± 0.08 × 10–9 1.30 ± 0.08 × 107 2.66 ± 0.16 × 10–9
04 3.50 ± 0.22 × 10–7 1.11 ± 0.11 × 105 3.12 ± 0.31 × 10–7
02 7.46 ± 0.97 × 10–5 2.29 ± 0.06 × 103 1.51 ± 0.04 × 10–5
05 9.36 ± 0.56 × 10–8 ND ND
2 4.80 ± 0.24 × 10–5 ND ND
04 4.87 ± 0.22 × 10–7 ND ND
tested (0.1 mM).
were calculated from the relationship, IC50 = ln2/(ki × t), where
yme, ln2 = natural logarithm of 2 = 0.693, ki = bimolecular rate
0 min. Units are M–1 min–1 for ki and M for IC50. Hen and mouse
in homogenates. Human acetylcholinesterase was assayed in
Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jat
1429
Table 2. Experimental ki and calculated 20-min IC50 values for organophosphorus inhibitors against different species of NTE or
NESTa
Inhibitor Species
Hen Mouse Human
ki IC50 ki IC50 ki IC50
CPS NI ND NI ND NI ND
CPO 4.00 ± 0.76 × 105 8.66 ± 1.65 ×10–8 4.53 ± 1.09 × 105 7.65 ± 1.84 ×10–8 1.54 ± 0.33 × 105 2.25 ± 0.48 ×10–7
DFP 6.37 ± 0.26 × 104 5.44 ± 0.22 ×10–7 3.08 ± 0.39 × 104 1.12 ± 0.14 ×10–6 3.75 ± 0.24 × 104 9.24 ± 0.59 ×10–7
MIP 4.66 ± 0.49 × 103 7.44 ± 0.78 ×10–6 1.37 ± 0.13 × 103 2.53 ± 0.24 ×10–5 4.34 ± 0.14 × 103 7.98 ± 0.26 ×10–6
PrDChVP 1.25 ± 0.11 × 106 2.77 ± 0.24 ×10–8 1.44 ± 0.06 × 106 2.41 ± 0.10 ×10–8 ND ND
diEt-PFP 2.50 ± 0.14 × 102 1.39 ± 0.08 ×10–4 1.22 ± 0.05 × 102 2.84 ± 0.12 ×10–4 ND ND
diBu-PFP 1.27 ± 0.09 × 106 2.73 ± 0.19 ×10–8 5.11 ± 0.23 × 105 6.78 ± 0.30 ×10–8 ND ND
ND, not determined; NEST, neuropathy target esterase domain; NI, no inhibition of either enzyme at the highest concentration
tested (0.1 mM); NTE, neuropathy target esterase.
aValues are mean ± SEM (n = 3 or 4). Fixed-time (20-min) IC50 values were calculated from the relationship, IC50 = ln2/(ki × t), where
IC50 = inhibitor concentration to produce 50% inhibition of the enzyme, ln2 = natural logarithm of 2 = 0.693, ki = bimolecular rate
constant of inhibition, and t = preincubation time with inhibitor = 20 min. Units are M–1 min–1 for ki and M for IC50. Hen NTE activity
was assayed in 9S or lyophilized membrane fractions from brain homogenates. Mouse NTE activity was assayed in 9S fractions
from brain homogenates. Human NEST activity was assayed in preparations from human recombinant NEST.
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Figure 2. Correlations of log ki for inhibition of AChE. (A) mouse brain and hen brain AChE; (B) mouse brain and human recombinant AChE; (C) human
recombinant AChE and hen brain AChE. ki = bimolecular rate constant of inhibition (M
–1min–1). AChE, acetylcholinesterase.
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Table 3. Relative inhibitory potential for organophosphorus
inhibitors against NTE or NEST vs. AChE from different speciesa
Inhibitor Species
Hen Mouse Human
CPS NI NI NI
CPO 0.030 ± 0.006 0.036 ± 0.009 0.012 ± 0.003
DFP 0.45 ± 0.024 0.30 ± 0.02 0.34 ± 0.04
MIP 4.09 ± 0.51 2.98 ± 0.41 1.90 ± 0.08
PrDChVP 3.47 ± 0.33 3.90 ± 0.28 ND
diEt-PFP 0.23 ± 0.018 0.17 ± 0.011 ND
diBu-PFP 7.10 ± 0.74 7.30 ± 0.46 ND
AChE, acetylcholinesterase; ND, not determined; NEST, neu-
ropathy target esterase domain; NI, no inhibition of either
enzyme at the highest concentration tested (0.1 mM); NTE,
neuropathy target esterase.
aData are mean ± SEM. Relative inhibitory potential = [ki(NTE
or NEST)/ki(AChE)]; where ki = bimolecular rate constant of
inhibition; n = 3 – 4 for each ki (from Tables 1 and 2). Hen
and mouse AChE activity was assayed in 9S fractions from
brain homogenates. Human AChE was assayed in prepara-
tions from commercial recombinant enzyme. Hen NTE activ-
ity was assayed in 9S or lyophilized membrane fractions from
brain homogenates. Mouse NTE activity was assayed in 9S
fractions from brain homogenates. Human NEST activity
was assayed in preparations from human recombinant NEST.
Mouse model for biochemical OPIDN assessmentAcute toxicity determination
LD50 values and their 95% CI for outbred white male mice (i.p.
administration; 24 h observation period) were 15 (13.4–17.3)
mg kg–1 for PrDChVP, 200 (148.3–251.7) mg kg–1 for diEt-PFP
and > 2000 mg kg–1 for diBu-PFP.Discussion
The objective of the present work was to provide corroborating
and new data to help establish the use of mouse brain AChE and
NTE in vitro and in vivo for biochemical assessment of the
potential for OP compounds to produce OPIDN. In vitro assays
could be used for toxicodynamic assessment of directly acting-2.5
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J. Appl. Toxicol. 2014; 34: 1426–1435 Copyright © 2014 Johninhibitors, whereas dosing in vivo could be used to incorporate
toxicokinetic factors of absorption, distribution, metabolism
(activation and/or deactivation) and excretion into the assessment.
The OP compounds selected for the present study included
CPS, CPO, DFP, MIP, PrDChVP, diEt-PFP and diBu-PFP. Among
these, CPS is a pro-toxicant that requires metabolic activation
to its oxon, CPO, to inhibit serine esterases (Richardson, 1995).
Thus, CPS served as an OP control for CPO in our in vitro experi-
ments. CPO is a predominantly cholinergic OP compound,
whereas DFP, MIP and PrDChVP are intermediate between cho-
linergic and neuropathic, but each capable of producing OPIDN
(Kropp and Richardson, 2003; Makhaeva et al., 1995, 2003,
2009b). PrDChVP was intensively studied in our previous work
in experiments in vitro and in vivo using both hens and rats
(Makhaeva et al., 1995, 2003, 2009b). Two new experimental
compounds, diEt-PFP and diBu-PFP, were chosen for their differ-
ing hydrophobicity and demonstrated variations in neuropathic
potential in our preliminary in vitro experiments using human
erythrocyte AChE and hen brain NTE (Makhaeva et al., 2008).
Our choice of enzymes was based on the concept that the
ability of an OP compound to produce OPIDN depends on its
RIP toward NTE, the target for initiating OPIDN, and AChE, the
target for producing cholinergic toxicity. Although in some pre-
vious work we have deﬁned the RIP as its inverse (Kropp and
Richardson, 2003; Richardson, 1992; Richardson et al., 1993), in
the present study, we deﬁne the ratio as it was originally
proposed, RIP = ki(NTE)/ki(AChE = IC50(AChE)/IC50(NTE). By this
deﬁnition, if the RIP is < 1, then the compound is predicted to
produce cholinergic toxicity of sufﬁcient severity that it cannot
produce OPIDN at doses less than the LD50; however, if the RIP is
> 1, then the compound is predicted to produce OPIDN at doses
less than the LD50 (Lotti and Johnson, 1978; Malygin et al., 2003).
Our results demonstrate that the neuropathic potential of OP
compounds can be predicted from RIP values obtained by mea-
suring inhibitory potencies against AChE and NTE activities in 9S
fractions from hen or mouse brain homogenates or against
preparations of human recombinant AChE and NEST. These
in vitro ﬁndings conﬁrm and extend previous work using mouse
brain homogenates (Quistad et al., 2002), hen or human brain
homogenates (Capodicasa et al., 1991; Emerick et al., 2012; Lotti
and Johnson, 1978; Richardson et al., 1993) hen brain particulate
fractions (Makhaeva et al., 2013; Malygin et al., 2003; Sogorb
et al., 2010) or preparations from human or murine cell cultures
(Ehrich et al., 1997; Li and Casida, 1997; Sogorb et al., 2010). In Human 
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Figure 5. Inhibition of NTE and AChE activities in mouse brain 1 h after i.p. administration of increasing doses of (A) PrDChVP; (B) diEt-PFP; (C) diBu-
PFP (C) Data are presented as percentage inhibition of the corresponding esterase in the control animals. Esterase activities in mouse brain of the
control animals, nmol/(min × mg protein), (mean ± SEM): AChE = 69.20 ± 3.54 (n = 20), NTE =13.44 ± 0.52 (n = 10). AChE, acetylcholinesterase; NTE,
neuropathy target esterase.
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on the neuropathic potential of PrDChVP and two new com-
pounds, diEt-PFP and diBu-PFP.
Although inhibitory potencies of OP compounds can be
estimated by directly measuring ﬁxed-time IC50 in tissue prepa-
rations, extrinsic interactions with other proteins can introduce
substantial error into determinations of intrinsic sensitivity of
target enzymes to these inhibitors (Mortensen et al., 1998). More-
over, because ﬁxed-time methods cannot follow the progressive
nature of the inhibition or establish whether ideal pseudo-ﬁrst-
order conditions have been met (Fukuto, 1990; Richardson et al.,
1993), we used kinetic methods in the present study to determine
bimolecular rate constants of inhibition (ki) as measures of inhibi-
tory potency. However, once ki values have been determined, it
is valid to use the relationship IC50 = ln2/(ki × t) to calculate
corresponding IC50 values for comparison with those obtained in
other studies by ﬁxed-time methods (Aldridge and Reiner, 1972;
Richardson, 1992). Accordingly, the calculated 20 min IC50 values
obtained from the ki determinations in the present study are listed
in Tables 1 and 2. Whenmaking comparisons, it should be borne in
mind that both ki and IC50 are temperature-dependent within the
thermal limits of the enzyme, with ki increasing with increasing
temperature and IC50 decreasing with increasing temperature,
and that unlike the ki, the ﬁxed-time IC50 is by deﬁnition time-
dependent, decreasing in value with increasing time of incubation
of enzyme with inhibitor.
The ﬁxed-time IC50 values calculated for the hen brain
enzymes in the present work are consistent with previously
reported values by either falling within the range or being within
1 standard error for MIP (Kropp and Richardson, 2003;
Richardson et al., 1993), DFP (Atkins and Glynn, 2000; Lotti and
Johnson, 1978); CPO (Atkins and Glynn, 2000; Correll and Ehrich,
1987; Kropp and Richardson, 2003; Lotti and Johnson, 1978) and
PrDChVP (Lotti and Johnson, 1978; Makhaeva et al., 1995, 2003).
Regarding mouse brain enzymes, our calculated IC50 values
are again in good agreement for DFP (Ehrich et al., 1997; Quistad
et al., 2002) and MIP (Ehrich et al., 1997; Quistad et al., 2001), but
lower than those previously published for CPO (Ehrich et al.,
1997; Quistad et al., 2002). However, Ehrich et al. (1997) used mu-
rine neuroblastoma cells rather than mouse brain tissue, and the
incubation with OP compounds was for 1 h rather than 20 min;
moreover, the authors stated that at the concentrations of
inhibitors used, inhibition reached a plateau by 30 min. Quistad
et al. (2001, 2002) determined the IC50 at 25
○C for 15 min ratherCopyright © 2014 Johnwileyonlinelibrary.com/journal/jatthan 37 ○C for 20 min. These discrepancies serve to highlight the
fact that IC50 values for progressive inhibition of esterases by OP
compounds are by deﬁnition time-dependent and might not
have been determined under ideal pseudo-ﬁrst-order inhibition
conditions.
Our calculated IC50 values for human recombinant enzymes
aligned well with literature values for human or human recombi-
nant enzymes for MIP and DFP (Atkins and Glynn, 2000; Ehrich
et al., 1997; Kropp and Richardson, 2006; Kropp et al., 2004; Lotti
and Johnson, 1978), as well as human neuroblastoma NTE
inhibited by CPO (Ehrich et al., 1997). The apparent IC50 reported
by Ehrich et al. (1997) for human neuroblastoma AChE inhibited
by CPO was approximately 10-fold lower than our value. In
contrast, Amitai et al. (1998) used kinetic methods and obtained
a ki for inhibition of human recombinant AChE by CPO at 25
○C
that was about 70% of our value at 37 ○C.
Overall, the ﬁxed-time IC50 values calculated from kinetically
determined ki values in this study agree well with literature
values. In addition, as shown in Figs 2 and 3, correlations of
log ki values determined in the present study showed strong
correlations (r > 0.99) across species. However, to make predic-
tions about neuropathic potential, it is more important to exam-
ine ratios of ki or IC50 values (RIP values) rather than to scrutinize
the individual ki or IC50 values. Thus, we found that the calcu-
lated RIP value of CPO is much less than 1, meaning that it is
not likely to cause OPIDN at doses less than the LD50. Moreover,
we found that the RIP of DFP is slightly less than 1, indicating
neuropathicity at doses near the LD50, and that the RIP for MIP
and PrDChVP is slightly higher than 1, which signiﬁes that these
compounds are neuropathic. These results correspond with
previously published data (Kropp and Richardson, 2003; Lotti
and Johnson, 1978; Makhaeva et al., 2003). Furthermore, earlier
studies of other OP compounds in vitro have shown similar
correlations of neuropathic potential with RIPs determined from
human and hen brain tissues as well as neuroblastoma cell lines
of both human and murine origin (Ehrich et al., 1997; Lotti and
Johnson, 1978). In addition, as shown in Fig. 4, log RIP values
obtained in the present study were strongly correlated across
species (r > 0.979), despite not reaching the customary value
for statistical signiﬁcance (P < 0.05) in comparison with human
enzymes for which only three data pairs were available. In partic-
ular, these strong correlations indicate that the same conclu-
sions about neuropathic potential would be reached using
human recombinant, hen brain or mouse brain enzymes.J. Appl. Toxicol. 2014; 34: 1426–1435Wiley & Sons, Ltd.
Mouse model for biochemical OPIDN assessment
143In order to model all aspects of OPIDN, >70% of neural NTE
must be inhibited and aged in hens, and this can be induced
in a single dose of a neuropathic OP compound (Johnson,
1982). Moreover, the clinical course and spatial–temporal distri-
bution of axonal lesions in the hen closely mimics OPIDN in
humans, making the hen the standard for testing OP com-
pounds for delayed neuropathic potential (Doherty, 2006;
Emerick et al., 2012). At the same time, in vivo studies of OPIDN
in mice have proved to be more difﬁcult; initially it appeared
that OPIDN could be produced only if a neuropathic compound
were administered chronically (Lapadula et al., 1985). Further-
more, a potent NTE inhibitor known to induce OPIDN in hens
produces an acute neurotoxic syndrome with brain edema in
mice (Winrow et al., 2003; Wu and Casida, 1995, 1996). Finally,
although NTE inhibition and axonopathy could be produced in
mice following a single dose of a neuropathic OP compound
(Read et al., 2010; Veronesi et al., 1991), clinical signs of OPIDN
are not apparent in this species. Nevertheless, the objective of
the present study was not to produce a complete model of
OPIDN in the mouse; rather, our intent was to demonstrate that
the mouse could serve as a source of brain AChE and NTE for
biochemical assessment of the neuropathic potential of OP
compounds in vitro and in vivo.
For in vivo work in the present study, we selected three
compounds: PrDChVP, diEt-PFP and diBu-PFP. PrDChVP was
intensively studied in our previous works in experiments in vivo
both in hens and in rats (Makhaeva et al., 1995, 2003,
2009a, 2009b). In both species, this compound showed dose-
dependent inhibition of brain NTE and AChE. In hen experiments,
i.m. administration was used with subsequent determination of
NTE and AChE activity 24 h after administration (Makhaeva et al.,
1995, 2003, 2009b), and in rat experiments NTE and AChE activities
were determined 1 h after i.p. administration (Makhaeva et al.,
1995). Based on these results, in the present study in mice, we
used i.p. administration of PrDChVP with an assay of NTE and
AChE 1 h after dosing.
As shown in Fig. 4A, inhibition of NTE to the 70% threshold
thought to be required for initiation of OPIDN (Johnson, 1982;
Lotti, 1992; Moretto, 1998) was achieved by PrDChVP at a dose
of 10 mg kg–1, which is lower than the LD50 of 15 mg kg
–1. In
hen brain, 70% NTE inhibition occurred at a dose of 0.6 mg
kg–1 (Makhaeva et al., 1995, 2003), indicating that mice are less
sensitive than hens to this neuropathic OP compound. In
addition, the ED50 values calculated from the dose–response
curves in Fig. 4A were 4.34 ± 0.55 mg kg–1 for AChE and 2.17 ±
0.37 mg kg–1 for NTE. From our previous work on hens (Makhaeva
et al., 1995, 2003, 2009b), we have calculated the ED50 for AChE as
0.8 ± 0.1 mg kg–1 and 0.44 ± 0.01mg kg–1 for NTE, again indicating
that the mouse is less sensitive than the hen to inhibition of brain
AChE and NTE by PrDChVP. Nevertheless, despite the species
difference in sensitivity in vivo, the ratio ED50(AChE)/ED50(NTE),
which is the in vivo counterpart of the RIP (Malygin et al., 2003;
Richardson, 1992), is quite close for both species: 2.0 for mice
and 1.8 for hens. This result serves to support the validity of the
mouse model for biochemical assessment of the neuropathic
potential of OP compounds.
Further in vivo assessment was carried out using diEt-PFP and
diBu-PFP. These compounds were chosen based on their charac-
teristics determined in vitro (Tables 1–3). The compounds
differed markedly in RIP; diEt-PFP was less neuropathic than
the more hydrophobic diBu-PFP compound. Additionally, there
is abundant information on the differing neuropathic potentialJ. Appl. Toxicol. 2014; 34: 1426–1435 Copyright © 2014 Johnof OP compounds with diethyl vs. dibutyl substituents (Davis
et al., 1985; Johnson, 1975 1988).
We found that diEt-PFP is a weak inhibitor of NTE and AChE
in vivo (Fig. 5B). At a dose of 200 mg kg–1, which corresponds to
the LD50 of this compound, NTE activity was reduced only by
10% and AChE was decreased by 26%. The fact that a higher dose
than the LD50 would be required to reach the threshold of 70%
NTE inhibition agrees with our in vitro data on this compound.
In contrast, as shown in Fig. 5C, 70% NTE inhibition was
achieved at a dose 200 mg kg–1, which was substantially lower
than the estimated LD50 of > 2000 mg kg
–1. These results indi-
cate that diBu-PFP, with its low acute toxicity, might initiate
OPIDN at doses that do not produce warning signs of acute cho-
linergic poisoning. Indeed, the ED50 values for this compound
were 516 ± 83.9 mg kg–1 for AChE and 127 ± 7.5 mg kg–1 for
NTE, giving an ED50 ratio of 4.1. Thus, the in vivo result for
diBu-PFP agrees with our in vitro predictions, which indicates
distinct neuropathic potential for this compound.
In conclusion, although hens have been historically used as
the standard for testing neuropathic OP compounds, the data
from the present study demonstrate that relative inhibition of
AChE and NTE in the 9S fraction of mouse brain homogenates
may serve as an in vitro toxicodynamic model for neuropathic
potential assessment of directly acting inhibitors. In addition, rel-
ative inhibition of AChE and NTE in mouse brain after dosing
with OP compounds can provide a model for the biochemical
assessment of neuropathic potential with the added beneﬁt of
incorporating toxicokinetic factors. Future work should include
testing the mouse model with OP compounds that require
metabolic activation to be AChE and NTE inhibitors. In addition,
because aging of inhibited NTE appears to be required for initi-
ation of OPIDN, assays for aging should be incorporated as has
been done in other recent work (Sogorb et al., 2010).Acknowledgments
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